Log in

ASX:PYCPYC Therapeutics Stock Price, Forecast & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
PYC Therapeutics Limited provides drug discovery research and development services utilizing Phylomer peptide libraries and proprietary screening capabilities in Australia. The company's Phylomer libraries contain various peptides that represent a source of biologically active drug leads for a range of intracellular and extracellular disease targets. It develops next generation intracellular biological therapeutics, including its own preclinical Myc, STAT 5, and YB1 oncology inhibitor payloads using its proprietary cell penetrating functional penetrating Phylomers. The company has approximately 12 patent families comprising multiple granted/allowed patents in the United States and Australia, which cover methods of making the Phylomer libraries; methods of screening them and composition-of-matter claims for Phylomer libraries; and individual Phylomer peptides discovered for therapeutic and diagnostic applications. It has a research and development collaboration with Ramot. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.00 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology
Phone61 8 6151 0992



Sales & Book Value

Annual SalesN/A
Book ValueA$0.01 per share



Next Earnings DateN/A
OptionableNot Optionable

Receive PYC News and Ratings via Email

Sign-up to receive the latest news and ratings for PYC and its competitors with MarketBeat's FREE daily newsletter.

PYC Therapeutics (ASX:PYC) Frequently Asked Questions

Has PYC Therapeutics been receiving favorable news coverage?

News articles about PYC stock have trended negative on Sunday, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. PYC Therapeutics earned a news sentiment score of -2.2 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the near term. View the latest news about PYC Therapeutics.

Who are some of PYC Therapeutics' key competitors?

Who are PYC Therapeutics' key executives?

PYC Therapeutics' management team includes the following people:
  • Dr. Rohan Hockings J.D., MBBS (Hons.), G.D.L.P, Chief Strategy Officer & Director (Age 37, Pay $395k)
  • Mr. Douglas Huey, CEO & Director
  • Mr. Kevin Hart B.Com., F.C.A., B.Com, FCA, Company Sec. & CFO (Age 58)
  • Dr. Katrin Hoffmann, Chief Scientific Officer
  • Mr. Kaggen Ausma, Chief Bus. Officer

What is PYC Therapeutics' stock symbol?

PYC Therapeutics trades on the ASX under the ticker symbol "PYC."

How big of a company is PYC Therapeutics?

PYC Therapeutics has a market capitalization of $0.00.

What is PYC Therapeutics' official website?

The official website for PYC Therapeutics is pyctx.com.

How can I contact PYC Therapeutics?

The company can be reached via phone at 61 8 6151 0992.

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.